Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1994 1
1997 1
1998 1
1999 2
2001 2
2003 1
2004 2
2005 1
2006 5
2007 6
2008 9
2009 17
2010 25
2011 57
2012 96
2013 124
2014 165
2015 213
2016 324
2017 364
2018 526
2019 657
2020 772
2021 897
2022 1109
2023 1054
2024 1059
2025 1263
2026 279

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,002 results

Results by year

Filters applied: . Clear all
Page 1
HIV treatment and prevention 2019: current standards of care.
Phanuphak N, Gulick RM. Phanuphak N, et al. Curr Opin HIV AIDS. 2020 Jan;15(1):4-12. doi: 10.1097/COH.0000000000000588. Curr Opin HIV AIDS. 2020. PMID: 31658110 Review.
Present treatment regimens are potent, convenient, generally well tolerated and durable, and lead to a normal life expectancy. Present antiretroviral-based HIV prevention strategies focus on treating people with HIV infection with antiretrovirals as soon as feasible …
Present treatment regimens are potent, convenient, generally well tolerated and durable, and lead to a normal life expectancy. Present antir …
Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
Wang W, Zhao S, Wu Y, Duan W, Li S, Li Z, Guo C, Wang W, Zhang T, Wu H, Huang X. Wang W, et al. JMIR Public Health Surveill. 2023 Jul 27;9:e46767. doi: 10.2196/46767. JMIR Public Health Surveill. 2023. PMID: 37498645 Free PMC article.
BACKGROUND: HIV-1 infection continues to affect global health. Although antiretrovirals can reduce the viral load or prevent HIV-1 infection, current drugs require daily oral use with a high adherence level. ...According to the questionnaires, more than 85% of peopl …
BACKGROUND: HIV-1 infection continues to affect global health. Although antiretrovirals can reduce the viral load or prevent HIV …
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. Mayer KH, et al. Lancet. 2020 Jul 25;396(10246):239-254. doi: 10.1016/S0140-6736(20)31065-5. Lancet. 2020. PMID: 32711800 Free PMC article. Clinical Trial.
BACKGROUND: Tenofovir alafenamide shows high antiviral efficacy and improved renal and bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here, we report primary results from a blinded phase 3 study evaluating the efficacy and safety of pr …
BACKGROUND: Tenofovir alafenamide shows high antiviral efficacy and improved renal and bone safety compared with tenofovir disoproxil fumara …
Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, Katlama C, Slama L, Liegeon G, Beniguel L, Ohayon M, Mouhim H, Goldwirt L, Spire B, Loze B, Surgers L, Pavie J, Lourenco J, Ben-Mechlia M, Le Mestre S, Rojas-Castro D, Costagliola D; ANRS PREVENIR Study Group. Molina JM, et al. Lancet HIV. 2022 Aug;9(8):e554-e562. doi: 10.1016/S2352-3018(22)00133-3. Epub 2022 Jun 27. Lancet HIV. 2022. PMID: 35772417
INTERPRETATION: In this study, which enrolled mainly MSM, HIV-1 incidence on PrEP was low and did not differ between participants using daily PrEP and those using on-demand PrEP. On-demand PrEP therefore represents a valid alternative to daily …
INTERPRETATION: In this study, which enrolled mainly MSM, HIV-1 incidence on PrEP was low and did not differ between participa …
Virological safety of the UK blood supply in the era of individual risk assessments and HIV PrEP.
Maddox V, Vallely P, Brailsford SR, Harvala H. Maddox V, et al. Transfus Med. 2023 Oct;33(5):372-378. doi: 10.1111/tme.12993. Epub 2023 Sep 5. Transfus Med. 2023. PMID: 37668150 Review.
However, the increasing usage of pre-exposure prophylaxis (PrEP) to prevent acquisition of HIV infection after possible high-risk sexual contact within the UK blood donor population has been recently noted. It has brought with it new diagnostic challenges within blo …
However, the increasing usage of pre-exposure prophylaxis (PrEP) to prevent acquisition of HIV infection after possible high-r …
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ, Del Rio C, Fields SD, Marzinke MA, Eshleman SH, Donnell D, Spinelli MA, Kofron RM, Berman R, Piwowar-Manning EM, Richardson PA, Sullivan PA, Lucas JP, Anderson PL, Hendrix CW, Adeyeye A, Rooney JF, Rinehart AR, Cohen MS, McCauley M, Grinsztejn B; HPTN 083 Study Team. Landovitz RJ, et al. Lancet HIV. 2023 Dec;10(12):e767-e778. doi: 10.1016/S2352-3018(23)00261-8. Epub 2023 Nov 9. Lancet HIV. 2023. PMID: 37952550 Free PMC article. Clinical Trial.
BACKGROUND: Injectable cabotegravir was superior to daily oral tenofovir disoproxil fumarate plus emtricitabine for HIV prevention in two clinical trials. Both trials had the primary aim of establishing the HIV prevention efficacy of long-acting injectable cabotegra …
BACKGROUND: Injectable cabotegravir was superior to daily oral tenofovir disoproxil fumarate plus emtricitabine for HIV prevention in …
PrEP interest and HIV-1 incidence among MSM and transgender women in coastal Kenya.
Kimani M, van der Elst EM, Chiro O, Oduor C, Wahome E, Kazungu W, Shally M, Rinke de Wit TF, Graham SM, Operario D, Sanders EJ. Kimani M, et al. J Int AIDS Soc. 2019 Jun;22(6):e25323. doi: 10.1002/jia2.25323. J Int AIDS Soc. 2019. PMID: 31194291 Free PMC article.
We assessed HIV-1 incidence and pre-exposure prophylaxis (PrEP) interest in men who have sex with men exclusively (MSME), men who have sex with men and women (MSMW) and TGW in coastal Kenya. ...CONCLUSIONS: TGW had a very high HIV-1 incidence compared with MS …
We assessed HIV-1 incidence and pre-exposure prophylaxis (PrEP) interest in men who have sex with men exclusively (MSME), men …
Perceptions and attitudes regarding HIV pre-exposure prophylaxis (PrEP) among dermatology clinicians and trainees.
Delgado F, Hijab E, Siira M, Yeung H. Delgado F, et al. Arch Dermatol Res. 2023 Aug;315(6):1789-1792. doi: 10.1007/s00403-022-02500-6. Epub 2022 Dec 12. Arch Dermatol Res. 2023. PMID: 36504114 Free PMC article.
Substantial gaps in PrEP knowledge and discussion were reported despite prior HIV discrimination training and HIV-related practice experience. ...Addressing stigma among dermatologists and improving HIV PrEP education is vital to enhancing the h …
Substantial gaps in PrEP knowledge and discussion were reported despite prior HIV discrimination training and HIV-relat …
Lenacapavir: A novel injectable HIV-1 capsid inhibitor.
Hitchcock AM, Kufel WD, Dwyer KAM, Sidman EF. Hitchcock AM, et al. Int J Antimicrob Agents. 2024 Jan;63(1):107009. doi: 10.1016/j.ijantimicag.2023.107009. Epub 2023 Oct 14. Int J Antimicrob Agents. 2024. PMID: 37844807 Review.
Lenacapavir is a novel first-in-class inhibitor of HIV-1 capsid function with efficacy at various stages of the viral life cycle, and it is indicated for the treatment of MDR HIV-1 infection in combination with optimized background antiretroviral therapy. ...The uni …
Lenacapavir is a novel first-in-class inhibitor of HIV-1 capsid function with efficacy at various stages of the viral life cycle, and …
8,002 results